Literature DB >> 19822914

Torpedo maculopathy.

Pamela R Golchet1, Lee M Jampol, Jeevan R Mathura, Mark J Daily.   

Abstract

AIM: To describe the fluorescein angiographic, fundus autofluorescence and optical coherence tomography (OCT) findings in patients with a unique unilateral lesion of the temporal macula previously named torpedo maculopathy.
METHOD: This study was a retrospective, observational case series. The medical records of 13 patients, age 1-68 years, seen between 1982 and 2009 were reviewed. Patients were evaluated for lesion features and course on follow-up, visual acuity, fluorescein angiography, visual-field defects, fundus autofluorescence and OCT findings.
RESULTS: In all 13 patients, the lesion was flat, torpedo-shaped and solitary, and involved the temporal macula. The hypopigmented lesion had well-defined margins and a characteristic leading edge which pointed towards the centre of the macula. Fluorescein angiography revealed transmission hyperfluorescence of the lesion. OCT indicated a thin abnormal retinal pigment epithelium signal, and Humphrey Visual Field testing revealed a corresponding blind spot. Fundus autofluorescence performed on one patient was dark in the affected area.
CONCLUSION: Torpedo maculopathy is an apparently congenital hypopigmented torpedo-shaped lesion of the temporal macula. Although it may result in a corresponding visual-field defect, these non-foveal lesions do not affect central visual acuity.

Entities:  

Mesh:

Year:  2009        PMID: 19822914     DOI: 10.1136/bjo.2009.162669

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  [Hypopigmentation temporal to the macula. Case report: torpedo maculopathy].

Authors:  M S Bedar; F G Holz; T Lischka
Journal:  Ophthalmologe       Date:  2013-02       Impact factor: 1.059

2.  Torpedo maculopathy: disease spectrum and associated choroidal neovascularisation in a paediatric population.

Authors:  Katherine Shirley; Marie O'Neill; Rachel Gamble; Anne Ramsey; Eibhlin McLoone
Journal:  Eye (Lond)       Date:  2018-03-20       Impact factor: 3.775

3.  Optical coherence tomography and electrophysiological findings in torpedo maculopathy.

Authors:  Luca Buzzonetti; Sergio Petroni; Gino Catena; Giancarlo Iarossi
Journal:  Doc Ophthalmol       Date:  2014-12-09       Impact factor: 2.379

4.  Torpedo maculopathy: a morphofunctional evaluation.

Authors:  Elisabetta Pilotto; Maria Elisabetta Zannin; Enrica Convento; Marta Cortese; Edoardo Midena
Journal:  Int Ophthalmol       Date:  2012-08-21       Impact factor: 2.031

5.  Expanded clinical spectrum of enhanced S-cone syndrome.

Authors:  Suzanne Yzer; Irene Barbazetto; Rando Allikmets; Mary J van Schooneveld; Arthur Bergen; Stephen H Tsang; Samuel G Jacobson; Lawrence A Yannuzzi
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

6.  Clinical evaluation of torpedo maculopathy in an infant population with additional genetic testing for NEXMIF mutation.

Authors:  Gokhan Celik; Murat Gunay; Asli Vural; Osman Kizilay; Yasemin Kendir Demirkol; Muhammet Kazim Erol
Journal:  Eye (Lond)       Date:  2021-07-29       Impact factor: 4.456

7.  Congenital ocular toxoplasmosis with torpedo maculopathy and retinopathy of prematurity in a premature baby.

Authors:  Darakhshanda Khurram; Syed M Ali; Quan Dong Nguyen; Igor Kozak
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-13

8.  Hyperpigmented Torpedo Maculopathy with Pseudo-Lacuna: A 5-Year Follow-Up.

Authors:  Austin Rohl; Sushma Vance
Journal:  Case Rep Ophthalmol       Date:  2016-05-26

9.  Torpedo maculopathy: A primary choroidal capillary abnormality?

Authors:  Rohan Chawla; Amar Pujari; Vaishali Rakheja; Atul Kumar
Journal:  Indian J Ophthalmol       Date:  2018-02       Impact factor: 1.848

10.  Torpedo maculopathy with multifocal central serous chorioretinopathy: A rare case report.

Authors:  Pradeep Kumar Panigrahi; Anita Minj; Jasmita Satapathy
Journal:  Indian J Ophthalmol       Date:  2018-02       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.